BMS Reports Five-Year Data of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -214 for the Treatment of Advanced or Metastatic Renal Cell Carcinoma

September 16, 2021 Auto Bot BMS, Clinical Trials, ipilimumab, Nivolumab, Opdivo, P-III, Renal Cell Carcinoma, Yervoy 0

Shots:

  • The P-III CheckMate -214 trial evaluates Opdivo (3mg/kg) + Yervoy (1mg/kg, q3w for 4 doses) vs sunitinib in 1096 patients with previously untreated advanced/mRCC
  • Results: @median follow-up of 67.7mos., combination showed superior OS in intermediate, poor risk patients & randomized or ITT population; m-OS (47.0 vs 26.6mos.) & (55.7 vs 38.4mos.); ORR (42% vs 27%) & (39% vs 32%); DoR (not reached in all population vs 19.7 & 24.8mos.); CR rate (11% vs 2%) & (12% vs 3%); OS rates @ 5yrs. (43% and 31%) & (48% and 37%) respectively
  • Patients were alive (81% vs 72%), PFS (89% vs 57%), patients responded (89% vs 63%) @5yrs., safety profile was manageable & no new safety signals were observed

Click here to­ read full press release/ article | Ref: BMS | Image: BMS

The post BMS Reports Five-Year Data of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -214 for the Treatment of Advanced or Metastatic Renal Cell Carcinoma first appeared on PharmaShots.